Review Article
Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer’s Disease: A Review of Clinical Trials
Table 4
Clinical trials on treatment with donepezil in moderate-severe AD.
| First author and number in the list of references | Severity | Mean age years | Mean MMSE at baseline | Duration of the study | | Test |
| Carrasco et al. 2011 [23] | MMSE 1–23 | 74.4 (7.7) | Mild: 20.14 (4) Moderate: 15.9 (3.83) Severe: 11.3 (5.4) | 6 months | 455 | MMSE NPI
|
| Farlow et al. 2011, 2010 [24, 25] | MMSE 0–20 | 10 mg: 73.8 (8.56) 23 mg: 73.9 (8.53) | 10 mg: 13.0 (4.75) 23 mg: 13.1 (4.99) | 24 weeks | 1434 | MMSE ACDS-ADL-sev SIB CIBIC-plus |
|
Schwam and Xu 2010 [26] | MMSE 5–17 | Placebo: 74 Donepezil: 73.3 | Placebo: Donepezil: | 24 weeks | 290 | NPI SIB CIBIC-plus MMSE DAD |
| Homma et al. 2008 [27] | MMSE | Placebo: 5 mg: 10 mg: | Placebo: 5 mg: 10 mg: | 24 weeks | 325 | BEHAVE-AD ACDS-ADL-sev CIBIC-plus MMSE SIB |
| Black et al. 2007 [28] | MMSE | 78.0 (8.10) | Donepezil: 7.5 (325) Placebo: 7.4 (3.57) | 24 weeks | 343 | ACDS-ADL-sev CIBIC-plus MMSE SIB NPI CBQ |
|
|